ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » New Hampshire » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in New Hampshire

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ROBERT DEWEY M.D.

Cardiovascular Disease

1,761

$94.3K

198
179 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 23%

$54
Average prescription price

Avg: $72

WILLIAM BERNDT MD

Cardiovascular Disease

1,555

$104K

191
157 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 23%

$67
Average prescription price

Avg: $72

WILLIAM GRAFF M.D.

Cardiovascular Disease

1,486

$66.1K

183
154 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 23%

$44
Average prescription price

Avg: $72

SACHIN SAKSENA M.D.

Cardiovascular Disease

1,478

$74.2K

161
128 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 23%

$50
Average prescription price

Avg: $72

JEFFREY LOCKHART M.D.

Cardiovascular Disease

1,399

$42.8K

149
126 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 23%

$31
Average prescription price

Avg: $72

MICHAEL METZGER MD

Cardiovascular Disease

1,372

$85.1K

211
182 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 23%

$62
Average prescription price

Avg: $72

ANDREW COHEN M.D.

Cardiovascular Disease

1,314

$55K

182
157 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 23%

$42
Average prescription price

Avg: $72

ROBERT BURKE MD

Cardiovascular Disease

1,303

$69.9K

238
209 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 23%

$54
Average prescription price

Avg: $72

NICHOLAS SKIADAS M.D.

Cardiovascular Disease

1,300

$74.8K

104
90 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 23%

$58
Average prescription price

Avg: $72

ERNEST PODRASKY MD

Cardiovascular Disease

1,284

$73.4K

153
129 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 23%

$57
Average prescription price

Avg: $72

MICHAEL NEWTON M.D.

Cardiovascular Disease

1,280

$63.7K

114
103 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 23%

$50
Average prescription price

Avg: $72

MICHAEL JACUCH M.D.

Cardiovascular Disease

1,278

$111K

198
169 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 23%

$87
Average prescription price

Avg: $72

PHILIP FITZPATRICK M.D.

Cardiovascular Disease

1,273

$64.6K

233
202 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 23%

$51
Average prescription price

Avg: $72

EDWARD CATHERWOOD M.D.

Cardiovascular Disease

1,271

$895K

151
131 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 23%

$704
Average prescription price

Avg: $72

ALICE PASSER MD

Cardiovascular Disease

1,259

$66.6K

151
130 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 23%

$53
Average prescription price

Avg: $72

LOUIS FINK M.D.

Cardiovascular Disease

1,250

$68.5K

176
147 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 23%

$55
Average prescription price

Avg: $72

ALAN KAPLAN M.D.

Cardiovascular Disease

1,214

$65.5K

76
72 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 23%

$54
Average prescription price

Avg: $72

AYESHA NAZEER M.D.

Cardiovascular Disease

1,205

$46.8K

117
102 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

13%
prescriptions for brand name drugs

Avg: 23%

$39
Average prescription price

Avg: $72

JON WAHRENBERGER M.D.

Cardiovascular Disease

1,192

$64.4K

163
141 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 23%

$54
Average prescription price

Avg: $72

ROBERT CAPODILUPO M.D.

Cardiovascular Disease

1,148

$115K

147
120 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 23%

$100
Average prescription price

Avg: $72

ROBERT LOOTENS M.D.

Cardiovascular Disease

987

$40.3K

102
89 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 23%

$41
Average prescription price

Avg: $72

CRAIG BERRY M.D.

Cardiovascular Disease

952

$66.9K

116
102 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 23%

$70
Average prescription price

Avg: $72

KENNETH DELOGE M.D.

Cardiovascular Disease

943

$208K

109
92 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 23%

$220
Average prescription price

Avg: $72

DANIEL VAN BUREN M.D.

Cardiovascular Disease

847

$33.7K

143
119 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 23%

$40
Average prescription price

Avg: $72

BRUCE ANDRUS M.D.

Cardiovascular Disease

812

$166K

123
106 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$204
Average prescription price

Avg: $72

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank